COMMENT
As it looked at this in the last couple of months, but likes their Alzheimer's drug. Pure biotech, where they're burning money every quarter is not easy for him.
biotechnology / pharmaceutical
BUY
In general, he does not like Biotech's but he likes this company a lot. Looking at introducing therapy into the Alzheimer's stage, which would be disease altering, which would reverse the effects. Have good US partners. Likes for the long term.
biotechnology / pharmaceutical
BUY ON WEAKNESS
In diabetes and Alzheimer therapies. Alzheimer is a disease-altering drug, not just the symptoms. Could be 5 to 10 years. If you can, trade around the volatility. Excellent long-term upside.
biotechnology / pharmaceutical
BUY
In diabetes, but their big upside now is in their Alzheimer’s work. Their therapy is the only one that could be disease changing, not just the symptoms. It will take 5-7 years to prove it out.
biotechnology / pharmaceutical
STRONG BUY
Generally stays away from pure biotech. Interesting diabetes play, but likes it for the Alzheimer’s play. Has a drug that could be disease altering as opposed to symptom altering. It’ll be years before it comes through as a drug, but if it does, sales will be massive.
biotechnology / pharmaceutical
HOLD
Wouldn't be the best company in the biotechnology space. Not a bad company.
biotechnology / pharmaceutical
BUY
Has been consolidating around the $1 for some time. Seeing some selling pressures re: warrants that were converted. A relatively high risk name, but if they are successful across one or two of the different platforms they have, stock could be significantly higher. Good management team.
biotechnology / pharmaceutical
BUY
Likes the company. Even though it hasn't done a whole lot, it's starting to form a pretty good base. Now that the sector is a little bit better than it was, it is pretty ownable now.
biotechnology / pharmaceutical
BUY
Has a few products, but has one primary product in diabetes. If he gets it right, and the animal studies come through in humans, thinks the stock will go from $1 to over $10. The good news is that it has 2/3 other products coming up behind it, so if it drops, will only go down to $0.50.
biotechnology / pharmaceutical
BUY
Best to own a basket when owing smaller bio techs. Gigh risk/high return. Their diabetes drug, if it flows through, has a huge market potential. News flow has been fairly good. Still early stage. Good management.
biotechnology / pharmaceutical
BUY ON WEAKNESS
A pretty decent company. Got smeared with the same brush as Conjuchem. Doesn't expect anything this year as it will probably be sold as a tax loss. OK for the long term.
biotechnology / pharmaceutical
BUY ON WEAKNESS
Very solid management. A phase 2 drug. Overvalued considering the biotech market has dropped so much. Would be more interesting at $.80/$.90.
biotechnology / pharmaceutical
TOP PICK
Biotech world has had a tough time in the last month. This company is progressing well. Will take over the clinical development which is very lucrative for the company. Likes management and their pipeline.
biotechnology / pharmaceutical
TOP PICK
Has an interesting pipeline of products. An early stage product is a diabetes treatment.
biotechnology / pharmaceutical
BUY
Have the best animal model data that he has ever seen. If they can make the transition to human models, the stock would go to $10. Results could be out by the end of this year or the beginning of next.
biotechnology / pharmaceutical
Showing 1 to 15 of 17 entries

Transition Therapeutics Inc(TTH-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Transition Therapeutics Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Transition Therapeutics Inc(TTH-T) Frequently Asked Questions

What is Transition Therapeutics Inc stock symbol?

Transition Therapeutics Inc is a OTC stock, trading under the symbol TTH-T on the (). It is usually referred to as or TTH-T

Is Transition Therapeutics Inc a buy or a sell?

In the last year, there was no coverage of Transition Therapeutics Inc published on Stockchase.

Is Transition Therapeutics Inc a good investment or a top pick?

Transition Therapeutics Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Transition Therapeutics Inc.

Why is Transition Therapeutics Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Transition Therapeutics Inc worth watching?

In the last year 0 stock analysts on Stockchase covered Transition Therapeutics Inc. The stock is worth watching.

What is Transition Therapeutics Inc stock price?

On , Transition Therapeutics Inc (TTH-T) stock closed at a price of $.